Leukemia inhibitory factor (LIF)
- Author(s)
- Nicola, NA; Babon, JJ;
- Journal Title
- Cytokine Growth Factor Rev
- Publication Type
- Journal Article in press
- Abstract
- Leukemia inhibitory factor (LIF) is the most pleiotropic member of the interleukin-6 family of cytokines. It utilises a receptor that consists of the LIF receptor beta and gp130 and this receptor complex is also used by ciliary neurotrophic growth factor (CNTF), oncostatin M, cardiotrophin1 (CT1) and cardiotrophin-like cytokine (CLC). Despite common signal transduction mechanisms (JAK/STAT, MAPK and PI3K) LIF can have paradoxically opposite effects in different cell types including stimulating or inhibiting each of cell proliferation, differentiation and survival. While LIF can act on a wide range of cell types, LIF knockout mice have revealed that many of these actions are not apparent during ordinary development and that they may be the result of induced LIF expression during tissue damage or injury. Nevertheless LIF does appear to have non-redundant actions in maternal receptivity to blastocyst implantation, placental formation and in the development of the nervous system. LIF has also found practical use in the maintenance of self-renewal and totipotency of embryonic stem cells and induced pluripotent stem cells.
- Publisher
- Elsevier
- Research Division(s)
- Cancer And Haematology; Structural Biology
- PubMed ID
- 26187859
- Publisher's Version
- https://doi.org/10.1016/j.cytogfr.2015.07.001
- NHMRC Grants
- NHMRC/461219, NHMRC/1016647, NHMRC/637300, NHMRC/1078737,
- ARC Grants
- ARC/FT110100169,
- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2015-07-20 02:23:53
Last Modified: 2016-04-20 02:10:04